ProCE Banner Activity

CE

Advancing Care for Patients Receiving CAR T-Cell Therapy: New Evidence and Opportunities for Oncology Pharmacy Practice

Multimedia
Watch this on-demand webcast from a recent HOPA satellite symposium on CAR T-cells for hematologic malignancies, including new data, recent approvals, and treatment guidelines.

Pharmacists : 1.00 contact {hour} ({0.1} CEUs)

Released: April 28, 2022

Expiration: April 27, 2023

Share

Faculty

Craig Freyer

Craig Freyer, PharmD, BCOP

Clinical Pharmacy Specialist
Hematology/Oncology, Stem Cell Transplant, and Cellular Therapy
Department of Pharmacy
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Andrew Lin

Andrew Lin, PharmD, BCOP

Clinical Pharmacy Specialist
Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by ProCE, LLC
ProCE Banner

Supporters

Supported by an educational grant from

BMS

Target Audience

The target audience for this activity is pharmacists, including clinical, managed care, and specialty pharmacists, who care for patients with hematologic malignancies that are eligible for CAR T-cell therapy as well other stakeholders in hematology/oncology practice.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate the latest clinical safety and efficacy data guiding the selection and sequencing of CAR T-cell therapy based on disease, treatment, and patient factors
  • Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of patients with leukemia, B-cell lymphomas, or myeloma to improve outcomes and enhance survivorship
  • Manage toxicities associated with CAR T-cell therapy using available guidelines and online clinical resources and tools

Faculty Disclosure

Primary Author

Craig Freyer, PharmD, BCOP

Clinical Pharmacy Specialist
Hematology/Oncology, Stem Cell Transplant, and Cellular Therapy
Department of Pharmacy
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Craig W. Freyer, PharmD, BCOP, has disclosed that he has received consulting fees from Astellas, EUSA, and Servier.

Andrew Lin, PharmD, BCOP

Clinical Pharmacy Specialist
Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
New York, New York

Andrew Lin, PharmD, BCOP, has disclosed that he has received consulting fees from EUSA, Incyte, and Medexus.

Staff Disclosure

Staff

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kristen Morrow, PhD

Editorial Contributor

Kristen Morrow, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-090-H01-P has been assigned to this home study, application-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 65% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 28, 2022, through April 27, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65.00% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners in the management of patients with hematologic malignancies that are eligible for CAR T-cell therapy using a case-based approach with a strong focus on the thought processes needed to solve patient care problems.